Elite Pharmaceuticals Statistics
Total Valuation
Elite Pharmaceuticals has a market cap or net worth of 587.18 million. The enterprise value is 589.02 million.
| Market Cap | 587.18M |
| Enterprise Value | 589.02M |
Important Dates
The next estimated earnings date is Thursday, February 13, 2025.
| Earnings Date | Feb 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Elite Pharmaceuticals has 1.07 billion shares outstanding. The number of shares has increased by 2.67% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.07B |
| Shares Change (YoY) | +2.67% |
| Shares Change (QoQ) | -0.74% |
| Owned by Insiders (%) | 22.21% |
| Owned by Institutions (%) | n/a |
| Float | 831.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.05 |
| PB Ratio | 12.42 |
| P/TBV Ratio | 12.50 |
| P/FCF Ratio | 227.16 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 36.13, with an EV/FCF ratio of 227.87.
| EV / Earnings | -92.20 |
| EV / Sales | 8.28 |
| EV / EBITDA | 36.13 |
| EV / EBIT | 40.32 |
| EV / FCF | 227.87 |
Financial Position
The company has a current ratio of 3.52, with a Debt / Equity ratio of 0.24.
| Current Ratio | 3.52 |
| Quick Ratio | 2.41 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | 0.70 |
| Debt / FCF | 4.41 |
| Interest Coverage | 17.30 |
Financial Efficiency
Return on equity (ROE) is -13.83% and return on invested capital (ROIC) is 16.39%.
| Return on Equity (ROE) | -13.83% |
| Return on Assets (ROA) | 11.49% |
| Return on Capital (ROIC) | 16.39% |
| Revenue Per Employee | 1.11M |
| Profits Per Employee | -99,816 |
| Employee Count | 64 |
| Asset Turnover | 0.90 |
| Inventory Turnover | 2.68 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +290.90% in the last 52 weeks. The beta is 0.18, so Elite Pharmaceuticals's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | +290.90% |
| 50-Day Moving Average | 0.55 |
| 200-Day Moving Average | 0.29 |
| Relative Strength Index (RSI) | 48.52 |
| Average Volume (20 Days) | 1,458,159 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.88 |
Income Statement
In the last 12 months, Elite Pharmaceuticals had revenue of 71.17 million and -6.39 million in losses. Loss per share was -0.01.
| Revenue | 71.17M |
| Gross Profit | 31.83M |
| Operating Income | 14.61M |
| Pretax Income | -6.77M |
| Net Income | -6.39M |
| EBITDA | 16.12M |
| EBIT | 14.61M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 9.55 million in cash and 11.40 million in debt, giving a net cash position of -1.84 million or -0.00 per share.
| Cash & Cash Equivalents | 9.55M |
| Total Debt | 11.40M |
| Net Cash | -1.84M |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 47.27M |
| Book Value Per Share | 0.04 |
| Working Capital | 32.44M |
Cash Flow
In the last 12 months, operating cash flow was 4.27 million and capital expenditures -1.68 million, giving a free cash flow of 2.58 million.
| Operating Cash Flow | 4.27M |
| Capital Expenditures | -1.68M |
| Free Cash Flow | 2.58M |
| FCF Per Share | 0.00 |
Margins
Gross margin is 44.73%, with operating and profit margins of 20.53% and -8.98%.
| Gross Margin | 44.73% |
| Operating Margin | 20.53% |
| Pretax Margin | -9.52% |
| Profit Margin | -8.98% |
| EBITDA Margin | 22.65% |
| EBIT Margin | 20.53% |
| FCF Margin | 3.63% |
Dividends & Yields
Elite Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.67% |
| Shareholder Yield | -2.67% |
| Earnings Yield | -1.84% |
| FCF Yield | 0.44% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Elite Pharmaceuticals has an Altman Z-Score of 2.45. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.45 |
| Piotroski F-Score | n/a |